Both BRAF(V600E) inhibitors are approved for use in combination with a MEK inhibitor for treatment of advanced melanoma and demonstrate an example of a successful vertical pathway inhibitor combination (58, 59, 60). This evidence concerns the gene BRAF and melanoma.